Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.

Background: Central nervous system (CNS) brain metastasis of advanced non-small cell lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy comparison of two first-generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib as first-line treatment for CNS metastasis NSCLC patients with EGFR-sensitizing mutations is yet to be elucidated.

Methods: A retrospective analysis was done on cerebral metastasis rate after erlotinib or gefitinib as first-line treatment for advanced NSCLC patients with EGFR-sensitizing mutations.

The role of monoacylglycerol lipase (MAGL) in the cancer progress.

In recent years, metabolism is talked highly important in cancer research, especially the lipid metabolism. Researchers believe that the de novo fatty acid synthesis plays an important role in tumor development, while many studies illustrated that Endocannabinoids have anti-tumorigenic actions, including anti-proliferation, apoptosis induction, and anti-metastatic effects, MAGL as an important decomposing enzyme of both lipid metabolism and endocannabinoids system, additionally as a part of a gene expression signature contributes to different aspects of tumourigenesis.

[IFN-gamma promotes human monocytes to differentiate to untypical mature DC].

Aim: To explore the morphologic and phenotypic changes of monocytess in response to the stimulation of IFN-gamma, TNF-alpha and IFN-alpha.

Methods: Newly isolated monocytes from human PBMCs were treated with IFN-gamma, TNF-alpha or IFN-alpha. The phenotypic growth of monocytes with or without stimulation was observed by microscope.

Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.

Identification of cytotoxic T lymphocyte (CTL) epitopes from additional tumor antigens is essential for the development of specific immunotherapy of malignant tumors. CML28, a recently discovered cancer-testis (CT) antigen from chronic myelogenous leukemia, is considered to be a promising target of tumor-specific immunotherapy. Because HLA-A*0201 is one of the most common histocompatibility molecule in Chinese, we aim at identifying CML28 peptides presented by HLA-A*0201.